期刊文献+

应用TreeAge Pro软件实现基于Markov模型的成本-效果分析 被引量:9

Cost-effectiveness analysis based on Markov model using TreeAge Pro software
原文传递
导出
摘要 卫生经济学分析近年来愈发受到重视,开展卫生经济学研究需掌握相关软件的使用。TreeAge Pro软件是一款广泛应用于医药决策领域的软件,其可进行决策分析、成本-效果分析、Monte Carlo模拟等。该软件功能强大且具有良好的可视化效果,可根据疾病模型构建Markov疾病转归模型进行Markov分析,亦可根据其他需求建立决策树与影响图进行决策分析。本文采用实例剖析的方式对该软件基于Markov模型实现成本-效果分析进行简要介绍,并对主要图表结果进行解读。 Health economics analysis has become increasingly important in recent years. It is essential to master the use of relevant software to conduct research in health economics. TreeAge Pro software is widely used in the healthcare decision analysis. It can carry out decision analysis, cost-effectiveness analysis, and Monte Carlo simulation. With powerful functionlity and outstanding visualization, it can build Markov disease transition models to analyze Markov processes according to disease models and accomplish decision analysis with decision trees and influence diagrams. This paper introduces cost-effectiveness analysis based on Markov model with examples and explains the main graphs.
出处 《中国循证医学杂志》 CSCD 北大核心 2018年第1期116-120,共5页 Chinese Journal of Evidence-based Medicine
基金 国家重点研发计划专项基金课题(编号2016YFC0106302) 国家自然科学基金(编号:71373160)“十二五”国家科技支撑计划课题(编号:2013BA106804Y001)
关键词 卫生经济学 药物经济学 TreeAge PRO软件 MARKOV模型 成本一效果分析 Health economics Pharmacoeconomics TreeAge Pro software Markov model Cost-effectivenes sanalysis
  • 相关文献

参考文献4

二级参考文献38

  • 1李海涛,李士雪,夏慧,李士保.药物经济学评价在国际卫生决策领域的应用现状、问题与对策[J].中国卫生经济,2006,25(9):75-78. 被引量:9
  • 2朱铭来,丁继红.我国医疗保障制度再构建的经济学分析[J].南开经济研究,2006(4):58-70. 被引量:15
  • 3[1]Furlong W, Feeny D, Torrance G, et al. Guide to design and development of health - state utility ins instrumentation: Center for Health Eeonomics and Policy Analysis Working Paper. Hamilton, Ontario, Canada, McMaster University, 1990.
  • 4[2]FA Sonnenberg, JR Robert. Markov Models in Medical Decision Making: A practical Guide. Med Decis Making, 1993,13: 322.
  • 5[3]Briggs A, Sculpher Mark. An Introduction to Markov Modelling for Economic Evaluation. Pharmacoeconomics,1998,13(4) :397.
  • 6[4]D Naimark, MD Krahn, G Naglie, et al. Primer on Medical Decission Analysis: Part 5 - Working with Markvo Processes. Med Decis Making,1997,17:152.
  • 7O’Brien S,Deininger M,Pinilla-lbarz J,et al.NCCN Guidelines Version3.2014Panel Members Chronic Myelogenous Leukemia[EB/OL].[2014-05-12].http://wenku.baidu.com/link?url=IRhm3udtx EO5Ymmgp URky Qu2Pjxzoskan Y4yir AGf ALdhv Gc Ww Py7v Mb RPy_6HMUsww HNw NYLDy DEe Ilzp FZY9Fum Fk QBms Uj ZSg A1Gzy Dy.
  • 8Taylor M.An economic evaluation of dasatinib for the treatment of chronic myelogenous leukaemia in imatinib-resistant patients[R].York:University of York,2009.
  • 9Shah NP,Kantarjian HM,Kim DW,et al.Intermittent target inhibition with dasatinib100mg once daily preserves efficacy and improves tolerability in imatinib-resistant and intolerant chronic-phase chronic myeloid leukemia[J].J Clin Oncol,2008,26(19):3 204.
  • 10Shah NP,Kim DW,Kantarjian H,et al.Potent,transient inhibition of BCR-ABL with dasatinib100mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance,suboptimal response or intolerance to imatinib[J].Haematologica,2010,95(2):232.

共引文献63

同被引文献71

引证文献9

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部